References
- Witt LJ, Curran JJ, Strek ME. The Diagnosis and Treatment of Antisynthetase Syndrome. Clin Pulm Med. 2016;23(5):218–26.
- Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Practice & Research Clinical Rheumatology. 2020;34(4):101503.
- Trudzinski FC, Kaestner F, Schäfers HJ, Fähndrich S, Seiler F, Böhmer P, et al. Outcome of Patients with Interstitial Lung Disease Treated with Extracorporeal Membrane Oxygenation for Acute Respiratory Failure. Am J Respir Crit Care Med. 2016;193(5):527–33.
- Guérin C, Reignier J, Richard J-C, Beuret P, Gacouin A, Boulain T, et al. Prone Positioning in Severe Acute Respiratory Distress Syndrome. New England Journal of Medicine. 2013;368(23):2159–68.
- Grasso S, Stripoli T, De Michele M, Bruno F, Moschetta M, Angelelli G, et al. ARDSnet ventilatory protocol and alveolar hyperinflation: role of positive end-expiratory pressure. Am J Respir Crit Care Med. 2007;176(8):761–7.
- Papazian L, Forel J-M, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome. New England Journal of Medicine. 2010;363(12):1107–16.
- Zanframundo G FKS, Yoshida A, Dourado E, Bauer Ventura I, Rivero Gallegos D, Loganathan A, Sambataro G, Bozan F, Bae S, Lim D, Cheli M, Yamano Y, Bonella F, Corte T, Doyle T, Fiorentino D, Gonzalez-Gay M, Hudson M, Kuwana M, Lundberg I, Mammen A, McHugh N, Miller F, Montecucco C, Oddis C, Rojas-Serrano J, Schmidt J, Scirè C, Selva-O’Callaghan A, Werth V, Rozza D, Morosini M, Bozzini S, Cavagna L, Aggarwal R. . The Classification Criteria for Anti-Synthetase Syndrome (Class) Project [abstract] Arthritis Rheumatol. 2024; 76 (suppl 9). 2024 [Available from:
https://acrabstracts.org/abstract/the-classification-criteria-for-anti-synthetase-syndrome-class-project/ . - Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77(282):1019–38.
- Yang H, Chen Q, Sun C, Jin Q, Zhang L, Liu Q, et al. Clinical and prognostic associations of anti-Jo-1 antibody levels in patients with antisynthetase syndrome. Respir Res. 2024;25(1):222.
- Sodsri T, Petnak T, Ngamjanyaporn P. Clinical Characteristics of Anti-Synthetase Syndrome and Variables Associated with Interstitial Lung Disease and Mortality: A Retrospective Cohort Study. Journal of Clinical Medicine [Internet]. 2023; 12(21).
- Vuillard C, Pineton de Chambrun M, de Prost N, Guérin C, Schmidt M, Dargent A, et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study. Annals of Intensive Care. 2018;8(1):87.
- Kouranloo K, Dey M, Elwell H, Yioe V, Spencer LG, Cotton CV. Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review. Rheumatology. 2025;64(1):45–55.
- McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant. 2019;34(1):63–73.
- Benad M, DK, KH, KW, AK, MA. Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease. Clinical and Experimental Rheumatology 2022;40:483–8.
- Rheumatology AC. 2023 American College of Rheumatology (ACR) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease Guideline Summary. 2023.
- Omotoso BA, Ogden MI, Balogun RA. Therapeutic plasma exchange in antisynthetase syndrome with severe interstitial lung disease. J Clin Apher. 2015;30(6):375–9.
- Bozkirli DE, Kozanoglu I, Bozkirli E, Yucel E. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis. J Clin Apher. 2013;28(6):422–5.
- Eller P, Flick H, Schilcher G, Moazedi-Fürst F, Eller K, Talakic E, et al. Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series. BMC Pulm Med. 2021;21(1):13.
- Tekkatte R, Yadav P, Venkatachala SK, Dibbur V. A Successful Rescue Therapy with Plasma Exchange for Rapidly Progressive Interstitial lung Disease Associated Antisynthetase Syndrome. Indian Journal of Rheumatology. 2023;18(1).
- Dequeker J, Geusens P, Wielands L. Short and longterm experience with plasmapheresis in connective tissue diseases. Biomedicine. 1980;32(4):189–94.
- Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med. 2014;189(11):1374–82.
- Raff LA, Gallaher JR, Johnson D, Raff EJ, Charles AG, Reid TS. Time to Cannulation after ICU Admission Increases Mortality for Patients Requiring Veno-venous ECMO for COVID-19 Associated Acute Respiratory Distress Syndrome. Ann Surg. 2022;276(6):e659–e63.
- Hermann M, Laxar D, Krall C, Hafner C, Herzog O, Kimberger O, et al. Duration of invasive mechanical ventilation prior to extracorporeal membrane oxygenation is not associated with survival in acute respiratory distress syndrome caused by coronavirus disease 2019. Ann Intensive Care. 2022;12(1):6.
- Sampson C, Taylor J, Dyson L, Hassanein M. Life-threatening respiratory failure requiring extra-corporeal membrane oxygenation secondary to the anti-synthetase syndrome. J Intensive Care Soc. 2021;22(1):83–7.
- Pineton de Chambrun M, Hervier B, Chauveau S, Tandjaoui-Lambiotte Y, Combes A, Uzunhan Y. Tofacitinib in antisynthetase syndrome-related rapidly progressive interstitial lung disease. Rheumatology (Oxford). 2020;59(12):e142–e3.
- Lio KU, Li S. Anti-synthetase syndrome masquerading as recurrent pneumonia. BMJ Case Rep. 2023;16(6).
- Rubin J, Black KE, Hallowell RW, Witkin AS, Lydston M, Shelton K, et al. Veno-Venous Extracorporeal Membrane Oxygenation for Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest. 2021;160(6):2163–7.